ClinicalTrials.gg
RecruitingNCT06960577Updated Oct 8, 2026

Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

A Phase 2 interventional study of Durvalumab and Methotrexate in Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors and Methotrexate, sponsored by AstraZeneca. Recruiting at 59 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 8, 2026Site recruiting status changedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing durvalumab in Urinary Bladder Neoplasms — 4 open to participants now, 12 under way, 3 of them phase 3. durvalumab · Urinary Bladder Neoplasms.

Planned enrollment
5th of 19
150 · median 39
Started
2025
with 1 other
Phase 2
11 of 19
2 open now
Primary completion
2028-08
later than 8 of 11 live
Registered
17th of 19
by date
Lead sponsor
5 of 19
AstraZeneca

Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 17th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

4 of the 19 studies testing durvalumab in Urinary Bladder Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing durvalumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.

Read the detailed description

Not provided

03

Conditions studied

  • Urinary Bladder Neoplasms
  • Immune Checkpoint Inhibitors
  • Methotrexate
  • Vinblastine
  • Doxorubicin
  • Cisplatin
  • Gemcitabine

Keywords

  • Muscle-invasive Bladder Cancer
  • Bladder Cancer
  • Immunotherapy
  • Durvalumab
  • Perioperative Durvalumab
  • ddMVAC
  • Gemcitabine
  • Cisplatin
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional or mixed transitional cell histology
  • Participants must be planning to undergo radical cystectomy
  • Participants who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer
  • performance status of 0 or 1
  • Minimum of 12 weeks at first dose of study medication

Exclusion criteria

Exclusion criteria:

  • Evidence of lymph node (N2-N3) or (M1) disease
  • Inoperable tumour(s) with fixation to the pelvic wall on clinical examination
  • Prior exposure to immune-mediated therapy including, but not limited to, other anti , anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin
  • Current or prior use of medication within 14 days before the first dose of durvalumab
  • Any concomitant medication known to be with ddMVAC.
  • Uncontrolled intercurrent illness.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    ddMVAC cohort

    Durvalumab + chemotherapy, approximately 120 participants

    Drug: Durvalumab · Drug: Methotrexate · Drug: Vinblastine · Drug: Doxorubicin · Drug: Cisplatin

  • Experimental
    gem/cis cohort

    Durvalumab + chemotherapy; approximately 30 participants; closed to further enrolment

    Drug: Durvalumab · Drug: Gemcitabine · Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. The safety of neoadjuvant durvalumab combined with ddMVAC prior to radical cystectomy (RC).

    Incidence of Grade 3 or 4 possibly treatment-related adverse events observed from the first dose of neoadjuvant study treatment until RC or the corresponding prespecified endpoint-window end date for participants who do not undergo RC

    Time frame: Up to 6 months

Secondary outcomes

  1. The safety and tolerability of perioperative durvalumab combined with neoadjuvant therapy

    Incidence, severity, nature, seriousness, outcome and causality of treatment-emergent adverse events, including PRAEs, adverse events of special interest, immune-mediated adverse events and serious adverse events; adverse events leading to study treatment interruption or discontinuation; and clinically relevant laboratory abnormalities

    Time frame: Up to 2 years

  2. The efficacy of perioperative durvalumab combined with ddMVAC in terms of event-free survival (EFS).

    EFS is defined as the time from first neoadjuvant durvalumab + chemotherapy treatment until the earliest occurrence of any of the following events: * First recurrence of disease after RC * First documented progression in participants who were medically precluded from RC * Time of expected surgery in participants who refuse to undergo RC or failure to undergo RC in participants with residual disease * Death due to any cause. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.

    Time frame: Up to 3 years

  3. The efficacy of perioperative durvalumab combined with ddMVAC in terms of disease-free survival (DFS).

    DFS is defined as the time from the date of RC to the earliest of the first recurrence of disease post RC or death due to any cause. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.

    Time frame: Up to 3 years

  4. The efficacy of perioperative durvalumab combined with ddMVAC in terms of OS.

    OS is defined as the time from first neoadjuvant durvalumab + chemotherapy until death due to any cause. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.

    Time frame: Up to 3 years

  5. The efficacy of neoadjuvant durvalumab combined with ddMVAC followed by RC in terms of pathological complete response (pCR).

    pCR rate is defined as the proportion of participants whose pathologic staging is T0N0M0 as assessed per local pathology review using specimens obtained via RC. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.

    Time frame: Up to 3 years

  6. The efficacy of neoadjuvant durvalumab combined with ddMVAC followed by RC in terms of pathologic downstaging (pDS).

    pDS rate is defined as the proportion of participants whose pathologic staging is \<P2 per local pathology review using specimens obtained via RC. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.

    Time frame: Up to 3 years

07

Study locations

48 of 59 sites recruiting
  • Research Site
    Chermside, 4032, Australia
    Recruiting
  • Research Site
    Elizabeth Vale, 5112, Australia
    Recruiting
  • Research Site
    Heidelberg, 3084, Australia
    Recruiting
  • Research Site
    Hong Kong, Australia
    Recruiting
  • Research Site
    Kogarah, 2217, Australia
    Recruiting
  • Research Site
    Macquarie University, 2109, Australia
    Recruiting
  • Research Site
    Murdoch, 6150, Australia
    Recruiting
  • Research Site
    Port Macquarie, 2444, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    St Leonards, 2065, Australia
    Recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Recruiting
  • Research Site
    Jaú, 17210-080, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Natal, 59075-740, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Porto Alegre, 91350-200, Brazil
    Recruiting
  • Research Site
    Rio de Janeiro, 20230-130, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Santo André, 09060-650, Brazil
    Recruiting
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    São Paulo, 01246-000, Brazil
    Recruiting
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
  • Research Site
    London, Ontario N6A 5W9, Canada
    Recruiting
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
    Recruiting
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
  • Research Site
    Angers, 49055, France
    Recruiting
  • Research Site
    Angers, 49933, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Bordeaux, 33075, France
    Recruiting
  • Research Site
    Chambray-lès-Tours, 37170, France
    Recruiting
  • Research Site
    Dijon, 21079, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lille, 59037, France
    Recruiting
  • Research Site
    Lyon, 69008, France
    Recruiting
  • Research Site
    Marseille, 13009, France
    Recruiting
  • Research Site
    Montpellier, 34070, France
    Recruiting
  • Research Site
    Nice, 06189, France
    Recruiting
  • Research Site
    Nîmes, 30029, France
    Recruiting
  • Research Site
    Paris, 75010, France
    Recruiting
  • Research Site
    Paris, 75900, France
    Recruiting
  • Research Site
    Pierre-Bénite, 69310, France
    Recruiting
  • Research Site
    Poitiers, 86021, France
    Recruiting
  • Research Site
    Quint-Fonsegrives, 31130, France
    Recruiting
  • Research Site
    Rennes, 35000, France
    Recruiting
  • Research Site
    Rouen, 76230, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Strasbourg, 67033, France
    Recruiting
  • Research Site
    Suresnes, 92150, France
    Recruiting
  • Research Site
    Florence, 50139, Italy
    Recruiting
  • Research Site
    Orbassano, 10043, Italy
    Recruiting
  • Research Site
    Roma, 00144, Italy
    Recruiting
  • Research Site
    Amsterdam, 1066CX, Netherlands
    Recruiting
  • Research Site
    Nijmegen, 6500 HB, Netherlands
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Rotterdam, 3015 GD, Netherlands
    Recruiting
  • Research Site
    Barcelona, 08025, Spain
    Recruiting
  • Research Site
    Barcelona, 08035, Spain
    Recruiting
  • Research Site
    Barcelona, 08036, Spain
    Recruiting
  • Research Site
    Barcelona, 8003, Spain
    Recruiting
  • Research Site
    Girona, 17007, Spain
    Recruiting
  • Research Site
    Las Palmas de Gran Canaria, 35016, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lugo, 27003, Spain
    Recruiting
  • Research Site
    Madrid, 28033, Spain
    Recruiting
  • Research Site
    Madrid, 28040, Spain
    Recruiting
  • Research Site
    Santiago de Compostela, 15706, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2028, 39 months after the start.

Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 39 months is close to that.

Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Oct 2028 → Aug 2028 and completion Oct 2028 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 7, 2025
StartActual
May 15, 2025
Primary completionEst.
Aug 30, 2028was Oct 2028
CompletionEst.
Aug 30, 2028was Oct 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • Research Site · London, CanadaNot yet recruiting→Recruiting
  • Research Site · Montreal, CanadaNot yet recruiting→Recruiting
  • Research Site · Angers, FranceNot yet recruiting→Recruiting
  • Research Site · Bordeaux, FranceNot yet recruiting→Recruiting
  • Research Site · Pierre-Bénite, FranceNot yet recruiting→Recruiting
  • Research Site · Amsterdam, NetherlandsNot yet recruiting→Recruiting
  • Research Site · Rotterdam, NetherlandsNot yet recruiting→Recruiting
Oct 8, 2026
Primary completion
Oct 31, 2028→Aug 30, 2028
Oct 8, 2026
Study completion
Oct 31, 2028→Aug 30, 2028
Oct 8, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatientsParticipants must be planning to undergo radical cystectomy
  • EditedPatientsParticipants who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer
Exclusion criteria
  • EditedAny concomitant medication known to be contraindicated to the chemotherapy (with ddMVAC or gem/cis).
Oct 8, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe safety of neoadjuvant durvalumab combined with ddMVAC or gem/cis prior to radical cystectomy (RC).Time frame: Up to 6 months
Oct 8, 2026
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedThe safety and tolerability of perioperative durvalumab combined with ddMVAC or gem/cis.neoadjuvant therapyTime frame: Up to 2 years
  • EditedThe efficacy of perioperative durvalumab combined with ddMVAC or gem/cis in terms of event-free survival (EFS).Time frame: Up to 3 years
  • EditedThe efficacy of perioperative durvalumab combined with ddMVAC or gem/cis in terms of disease-free survival (DFS).Time frame: Up to 3 years
  • EditedThe efficacy of perioperative durvalumab combined with ddMVAC or gem/cis in terms of OS.Time frame: Up to 3 years
  • EditedThe efficacy of neoadjuvant durvalumab combined with ddMVAC or gem/cis followed by RC in terms of pathologicpathological complete response (pCR).Time frame: Up to 3 years
  • EditedThe efficacy of neoadjuvant durvalumab combined with ddMVAC or gem/cis followed by RC in terms of pathologic downstaging (pDS).Time frame: Up to 3 years
Oct 8, 2026
Title
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasiveInvasive Bladder Cancer (NIAGARA-2)
Oct 8, 2026
Design
Phase 3→Phase 2
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • Research Site · London, CanadaNot yet recruiting→Recruiting
    • Research Site · Montreal, CanadaNot yet recruiting→Recruiting
    • Research Site · Angers, FranceNot yet recruiting→Recruiting
    • Research Site · Bordeaux, FranceNot yet recruiting→Recruiting
    • Research Site · Pierre-Bénite, FranceNot yet recruiting→Recruiting
    • Research Site · Amsterdam, NetherlandsNot yet recruiting→Recruiting
    • Research Site · Rotterdam, NetherlandsNot yet recruiting→Recruiting
    Primary completion Oct 31, 2028→Aug 30, 2028
    Study completion Oct 31, 2028→Aug 30, 2028
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatientsParticipants must be planning to undergo radical cystectomy
    • EditedPatientsParticipants who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer
    Exclusion criteria
    • EditedAny concomitant medication known to be contraindicated to the chemotherapy (with ddMVAC or gem/cis).
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe safety of neoadjuvant durvalumab combined with ddMVAC or gem/cis prior to radical cystectomy (RC).Time frame: Up to 6 months
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedThe safety and tolerability of perioperative durvalumab combined with ddMVAC or gem/cis.neoadjuvant therapyTime frame: Up to 2 years
    • EditedThe efficacy of perioperative durvalumab combined with ddMVAC or gem/cis in terms of event-free survival (EFS).Time frame: Up to 3 years
    • EditedThe efficacy of perioperative durvalumab combined with ddMVAC or gem/cis in terms of disease-free survival (DFS).Time frame: Up to 3 years
    • EditedThe efficacy of perioperative durvalumab combined with ddMVAC or gem/cis in terms of OS.Time frame: Up to 3 years
    • EditedThe efficacy of neoadjuvant durvalumab combined with ddMVAC or gem/cis followed by RC in terms of pathologicpathological complete response (pCR).Time frame: Up to 3 years
    • EditedThe efficacy of neoadjuvant durvalumab combined with ddMVAC or gem/cis followed by RC in terms of pathologic downstaging (pDS).Time frame: Up to 3 years
    Design Phase 3→Phase 2
    Title Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasiveInvasive Bladder Cancer (NIAGARA-2)
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06960577
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 7, 2025
Start date
May 15, 2025
Primary completion
Aug 30, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion